financetom
TXT
financetom
/
Industrials
/
TXT
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Textron Inc.TXT
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

Textron Inc. operates in the aircraft, defense, industrial, and finance businesses worldwide.

It operates through six segments: Textron Aviation, Bell, Textron Systems, Industrial, Textron eAviation, and Finance.

The Textron Aviation segment manufactures, sells, and services business jets, turboprop and piston engine aircraft, and military trainer and defense aircraft; and offers maintenance, inspection, and repair services, as well as sells commercial parts.

Its Bell segment supplies military and commercial helicopters, tiltrotor aircrafts, and related spare parts and services.

The Textron Systems segment offers unmanned aircraft systems, electronic systems and solutions, advanced marine crafts, piston aircraft engines, live military air-to-air and air-to-ship training, weapons and related components, and armored and specialty vehicles.

Its Industrial segment offers blow-molded solutions, including conventional plastic fuel tanks and pressurized fuel tanks for hybrid vehicle applications, clear-vision systems, plastic tanks for catalytic reduction systems, and battery housing systems for use in electric vehicles primarily to automobile original equipment manufacturers (OEMs); and golf cars, off-road utility vehicles, recreational side-by-side and all-terrain vehicles, snowmobiles, light transportation vehicles, aviation ground support equipment, professional turf-maintenance equipment, and turf-care vehicles to golf courses and resorts, government agencies and municipalities, consumers, outdoor enthusiasts, and commercial and industrial users.

The Textron eAviation segment manufactures and sells light aircraft and gliders with electric and combustion engines; and provides other research and development initiatives related to sustainable aviation solutions.

Its Finance segment offers financing services to purchase new and pre-owned aircraft and Bell helicopters.

The company was founded in 1923 and is headquartered in Providence, Rhode Island.

Latest News >
Inflation vigil sees single stock sideshows
Inflation vigil sees single stock sideshows
May 14, 2024
A look at the day ahead in U.S. and global markets from Mike Dolan Macro markets have basically frozen ahead of this week's big U.S. inflation releases, with sideshow entertainment provided by a fresh burst in activity in so-called 'meme stocks' while earnings updates and deals sagas dominated overseas. With Wednesday's April consumer price report this week's focus, Tuesday's release...
Merchants Bancorp Prices $98 Million Common Stock Offering
Merchants Bancorp Prices $98 Million Common Stock Offering
May 14, 2024
05:45 AM EDT, 05/14/2024 (MT Newswires) -- Merchants Bancorp ( MBIN ) said late Monday it has priced an underwritten public offering of 2.4 million common shares at $43 per share for expected proceeds of about $98 million. The company also granted the underwriters a 30-day option to buy up to an additional 360,000 shares. The company said it plans...
--Waste Management Maintains Dividend at $0.75 per Share, Payable on June 21 to Shareholders of Record on June 7
--Waste Management Maintains Dividend at $0.75 per Share, Payable on June 21 to Shareholders of Record on June 7
May 14, 2024
05:50 AM EDT, 05/14/2024 (MT Newswires) -- Price: 210.99, Change: +0.17, Percent Change: +0.08 ...
Hutchmed Starts Phase 2/3 Trial of Surufatinib Combination Therapy in Pancreatic Cancer
Hutchmed Starts Phase 2/3 Trial of Surufatinib Combination Therapy in Pancreatic Cancer
May 14, 2024
05:54 AM EDT, 05/14/2024 (MT Newswires) -- Hutchmed ( HCM ) said Tuesday it started a phase 2/3 trial of its drug candidate surufatinib in combination with nab-paclitaxel, gemcitabine and Jiangsu Hengrui's camrelizumab as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma in China. The company said the trial's first patient received the first dose on May 8...
Copyright 2023-2026 - www.financetom.com All Rights Reserved